Reliability of data collection for the National Comprehensive Cancer Network (NCCN) non-Hodgkin lymphoma (NHL) multi-center outcomes database: A methodological approach

被引：0
|
作者：
Kho, M. E.
Lepisto, E. M.
Niland, J. C.
terVeer, A.
LaCasce, A. S.
Friedberg, J. W.
Weeks, J. C.
机构：
[1] Dana Farber Canc Inst, Hamilton, ON, Canada
[2] Natl Comprehens Canc Network, Jenkintown, PA USA
[3] City Hope Comprehens Canc Ctr, Duarte, CA USA
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Univ Rochester, Med Ctr, Rochester, NY 14642 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6525
引用
收藏
页数：1
相关论文
共 39 条
  • [21] First-line systemic therapy in metastatic non-small cell lung cancer (mNSCLC) patients treated at National Comprehensive Cancer Network (NCCN) institutions: An analysis from the NCCN Oncology Outcomes Database Project.
    Vandergrift, J. L.
    Mamet, R.
    Zornosa, C.
    Reid, M. E.
    Rabin, M. S.
    Ettinger, D. S.
    Kalemkerian, G. P.
    Otterson, G. A.
    Niland, J. C.
    Pisters, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [22] Patterns of use of 18-fluoro-2-deoxy-D-glucose positron emission tomography for initial staging of grade 1-2 follicular lymphoma and its impact on initial treatment strategy in the National Comprehensive Cancer Network Non-Hodgkin Lymphoma Outcomes database
    Abou-Nassar, Karim E.
    Vanderplas, Ann
    Friedberg, Jonathan W.
    Abel, Gregory A.
    Niland, Joyce
    Rodriguez, Maria A.
    Czuczman, Myron S.
    Millenson, Michael
    Crosby, Allison
    Gordon, Leo I.
    Zelenetz, Andrew D.
    Kaminski, Mark
    Lacasce, Ann S.
    LEUKEMIA & LYMPHOMA, 2013, 54 (10) : 2155 - 2162
  • [23] Content validation of the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Lymphoma Symptom Index-18 (NFLymSI-18) in indolent B-cell non-Hodgkin's lymphoma
    Hurt, Courtney N.
    Kaiser, Karen
    Shaunfield, Sara
    Webster, Kimberly A.
    Keating, Karen
    Boyken, Lara
    Duffey, Sara
    Garcia, Jessica
    Cella, David
    JOURNAL OF PATIENT-REPORTED OUTCOMES, 2024, 8 (01)
  • [24] Aggressive end-of-life (EOL) chemotherapy (CT) use in metastatic non-small cell lung cancer (mNSCLC): A National Comprehensive Cancer Network (NCCN) outcomes database analysis.
    Bickel, K. E.
    Niland, J. C.
    Mamet, R.
    Zornosa, C. C.
    Ettinger, D. S.
    Pisters, K.
    Otterson, G. A.
    Koczywas, M.
    Reid, M. E.
    Rabin, M. S.
    D'Amico, T. A.
    Earle, C.
    Pini, T. M.
    Kalemkerian, G. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [25] Patterns of Care for Patients (Pts) with Stage I Non-Small Cell Lung Cancer (NSCLC): Analysis of the National Comprehensive Cancer Network (NCCN) Oncology Outcomes Database, 2007-2011
    Kapadia, N. S.
    Bobiak, S.
    Zornosa, C.
    D'Amico, T.
    Pisters, K.
    Dexter, B.
    Niland, J.
    Hayman, J.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : S269 - S270
  • [26] Phase 2 multi-center study of tazemetostat (EPZ-6438), an inhibitor of enhancer of zeste-homolog 2 (EZH2), in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL).
    Morschhauser, Franck
    Salles, Gilles A.
    Le Gouill, Steven
    Radford, John A.
    McKay, Pamela
    Cartron, Guillaume
    Pimentel, Patricia J.
    Roche, Maria
    Blakemore, Stephen J.
    McDonald, Alice
    Warholic, Natalie
    Knight, Shelley
    Ho, Peter T. C.
    Ribrag, Vincent
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [27] Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation for Hodgkin and Non-Hodgkin Lymphoma: Secondary Analysis from Two Multi-Center Randomized Controlled Trials of Hematopoietic Cell Transplant Survivorship Interventions
    Mian, Agrima
    Wei, Wei
    Chakraborty, Rajshekhar
    Yi, Jean C.
    Preussler, Jaime M.
    Hill, Brian T.
    Cerny, Jan
    Deol, Abhinav
    Hahn, Theresa E.
    Hashmi, Shahrukh K.
    Jaglowski, Samantha
    Jim, Heather S. L.
    Khera, Nandita
    Loren, Alison W.
    McGuirk, Joseph P.
    Savani, Bipin N.
    Stiff, Patrick
    Uberti, Joseph P.
    Whalen, Victoria
    Wingard, John R.
    Reynolds, Jana
    Holtan, Shernan G.
    Wood, William A.
    Baker, K. Scott
    Syrjala, Karen L.
    Hamilton, Betty K.
    Majhail, Navneet S.
    BLOOD, 2022, 140 : 8019 - 8021
  • [28] R-CHOP, Followed by High Dose Therapy and Autologous Stem Cell Rescue (HDT/ASCR), and R-Hypercvad Have Equivalent Progression-Free Survival and Are Superior to R-CHOP Alone in Younger Patients with Mantle Cell Lymphoma: a Comparative Effectiveness Analysis From the National Comprehensive Cancer Network (NCCN) Non-Hodgkin's Lymphoma Outcomes Database Project
    LaCasce, Ann
    Vandergrift, Jonathan L.
    Rodriguez, Maria A.
    Crosby, Allison L.
    Lepisto, Eva M.
    Czuczman, Myron S.
    Nademanee, Auayporn P.
    Blayney, Douglas W.
    Gordon, Leo I.
    Millenson, Michael
    Vanderplas, Ann
    Abel, Gregory A.
    Zelenetz, Andrew D.
    Friedberg, Jonathan W.
    BLOOD, 2009, 114 (22) : 167 - 168
  • [29] A multi-center, open-label study to evaluate the safety and efficacy of pentostatin, cytoxan, and rituxan (PCR) in the treatment of previously untreated or treated, stage III or IV, low-grade B-cell non-Hodgkin lymphoma (NHL) or bulky stage II lymphoma
    Christiansen, N. P.
    Mena, R.
    Markan, Y.
    Pandit, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [30] Production of KTE-C19 (Anti-CD19 CAR T Cells) for ZUMA-1: A Phase 1/2 Multi-Center Study Evaluating Safety and Efficacy in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)
    Better, Marc
    Chiruvolu, Vijay
    Oliver, James
    Lowe, Emily
    Rossi, John M.
    Perez, Arianne
    Navale, Lynn
    Bot, Adrian
    MOLECULAR THERAPY, 2016, 24 : S115 - S115
1234